Effect of Food on the Bioavailability of Omadacycline in Healthy Participants

Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2017, Pages 321-327

  Tzanis, Evan ^a   Manley, Amy ^a   Villano, Stephen ^a   Tanaka, S Ken ^a   Bai, Stephen ^a   Loh, Evan ^a  

^a Transcept Pharmaceuticals Inc   (United States)

Author keywords

bioavailability; fasted; food effect; omadacycline; pharmacokinetics

Indexed keywords

OMADACYCLINE; ANTIINFECTIVE AGENT; FAT INTAKE; TETRACYCLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BUTTER; CALORIC INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; EGG; ELIMINATION HALF-LIFE; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MEAT; MILK; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOMNOLENCE; TABLET FORMULATION; BIOAVAILABILITY; CLINICAL TRIAL; DIET RESTRICTION; FAT INTAKE; HALF LIFE TIME; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TIME FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TETRACYCLINES; TIME FACTORS;

EID: 84994385924     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.814     Document Type: Article

References (21)

1. Honeyman L, Ismail M, Nelson M, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59:7044–7053.
2. Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58:1279-1283.
3. Dubois J, Dubois M, Martel J-F, Tanaka SK. In vitro activity of omadacycline against Legionella pneumophila. Presented at 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA. Poster P-1992.
4. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Presented at 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA. Poster C-614.
5. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Presented at 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA. Poster C-554.
6. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ. Activity of omadacycline tested against Staphylococcus aureus from a global surveillance program (2014). Presented at 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-21, 2015; San Diego, CA. Poster F-289.
7. Kim O, Leahy RG, Traczewski M, Macone A, Steenbergen J, Tanaka SK. Activity and efficacy of omadacycline against Clostridium difficile. Presented at 26th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID); April 9-12, 2016; Amsterdam, the Netherlands. Poster P-1325.
8. Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58:1127–1135.
9. Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:5650–5654.
10. Noel GJ, Draper MP, Hait H, Tanaka SK. Safety and efficacy of PTK 0796 (omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI). Presented at 23rd European Congress on Clinical Microbiology and Infectious Diseases, (ECCMID); March 31-April 3, 2012, London, UK. Poster P-694.
11. Tanaka SK, Chitra S, Garrity-Ryan L, Tzanis E, Loh E. A pooled analysis of two randomized multicenter, evaluator-blind studies comparing the safety and efficacy of omadacycline and linezolid for the treatment of complicated skin and skin structure infections. Presented at 26th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID); April 9-12, 2016, Amsterdam, the Netherlands. Poster P-1326.
12. Sun H, Maietta R, Machineni S, et al. A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects. Presented at 21st European Congress on Clinical Microbiology and Infectious Diseases (ECCMID); May 7-11, 2011, Milan, Italy. Poster P-1423.
13. Flarakos J, Du Y, Gu H, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline [published online ahead of print August 8, 2016]. Xenobiotica.
14. Tanaka SK, Tzanis E, Villano S. Effect of age and gender on the pharmacokinetics of the oral and IV omadacycline, A new class of aminomethylcyclines. Presented at 26th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID); April 9-12, 2016, Amsterdam, the Netherlands. Poster P-1318.
15. Ting L, Kovacs SJ, Prestgaard J, et al. An open-label study of the pharmacokinetics and safety of single IV and oral doses of omadacycline in subjects with mild, moderate, and severe hepatic impairment. Presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; Washington, DC. Poster A-1282.
16. Ting L, Sun H, Kovacs SJ, Klausner K, Tanaka SK. Pharmacokinetics of intravenous and oral PTK796, a new aminomethylcycline antibiotic. Presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA. Abstract K-124.
17. Department of Health and Human Services, Food and Drug Administration (DHHS), Center for Drug Evaluation and Research (US). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. December 2002.
18. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58:256–265.
19. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008;62(Suppl 1):i11–i16.
20. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41(Suppl 5):S333–S340.
21. Horn PT, Sutcliffe JA, Walpole SM, Leighton A. Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434, following multiple dose administration. Presented at 49th Infectious Diseases Society of America Annual Meeting; October 20-23, 2011; Boston, MA.